廣泛抗藥性鮑氏不動桿菌抗藥性機轉及院內感染危險因子

Drug Resistance Mechanism of Extensively Drug-resistant Acinetobacter baumannii (XDRAB) and Risk Factors of Healthcare-associated XDRAB Infections

詹明錦(Ming-Chin Chan)

指導教授 ： 方啟泰

國立臺灣大學/公共衛生學院/公共衛生碩士學位學程/碩士(2010年)

https://doi.org/10.6342/NTU.2010.00988

摘要

Acinetobacter baumannii（鮑氏不動桿菌，簡稱 A. baumannii）抗藥性問題近年來在醫療照護相關感染防治上日益受到重視，依據Taiwan Nosocomial Infections Surveillance System(TNIS)統計資料顯示：醫學中心及區域醫院加護病房 carbapenem-resistant A. Baumannii 的比率從 2003 年不到 20%，逐年上升至 2010年第三季已達約 70%，本研究探討在某醫學中心自 2008 年到 2010年 (25個月) 期間，extensively drug-resisitant A. baumannii (XDRAB) 院內感染菌株的 Integron 抗藥性基因及 OXA(oxacillinases) typing 的分型情形，以了解其水解酵素種類及抗藥性機制，並以脈衝電泳分型（Pulsed-Field Gel Electrophoresis Analysis, PFGE）釐清院內 XDRAB 菌株間相關性，配合病例對照研究 (病例組：對照組=1︰4 配對) 探討 XDRAB 院內感染的危險因子。研究結果顯示 25 株 XDRAB 中有 23 株所帶的 Integron 均為 class I，且其所帶的 Gene cassette 大小皆為 2300 kb。所有 XDRAB 菌株都不帶有 class II Integron。在 OXA typing 的分型部份，可以看到大部分都帶有 OXA 23 (21株，84%) 和 OXA 51 (25株，100%)。所有 XDRAB 菌株經過 PFGE 分型鑑定後，以相似度為 80% 做切點可以分成14大類，並無單一顯著分子型別，在研究期間發生 XDRAB 院內群聚感染可能性相對較低，但是考量環境因素仍無法完全排除。病例對照研究結果為：在單變項分析中，長期臥床、血液透析、氣切、使用glycopeptide、使用imipenem or meropenem、使用 anti-Pseudomonal penicillins、使用第四代 cephalosporins 等均為發生 XDRAB 院內感染之顯著危險因子；以多變項 conditional logistic regression 調整干擾作用後，長期臥床（adjusted odds ratio 5.2, 95%CI: 1.1–24.4）及使用 imipenem、meropenem、anti- Pseudomonal penicillins、或第四代 cephalosporins（adjusted odds ratio 4.3, 95%CI: 1.4–12.7）兩變項均為發生 XDRAB 院內感染之獨立危險因子。本研究結論為：適當管制後線抗革蘭氏陰性菌抗生素的使用，為防治 XDRAB 院內感染不可或缺的一環。

關鍵字

廣泛抗藥性鮑氏不動桿菌 ； 脈衝電泳分型 ； 病例對照研究

並列摘要

The emergence of drug-resistant Acinetobacter baumannii (A. baumannii) is now a serious problem in healthcare-associated infections (HAIs) control. Data from Taiwan TINS showed that, while the percentage of carbapenem-resistant A. baumannii (CRAB) in ICU of medical centers/regional hospitals was less than 20% in 2003, it rose to 70% in Q3 2010. The objective of this study is to investage the distribution of integron drug-resistant gene and OXA typing of carbapenemase in extensively drug-resisitant A. baumannii (XDRAB) isolates from XDRAB-HAIs cases (2008~2010, 25 months). We also used pulsed-field gel electrophoresis (PFGE) to investigate the linkage between XDRAB strains. The risk factors of XDRAB-HAIs were investigated using case-control study (case: control=1:4). The result shows that 23 of 25 XDRAB isolates habored class I integron with a 2300-kb gene cassette. None carries class II integron. Most isolates had carry OXA 23 (n=21, 84%) and OXA51 (n=25, 100%). PFGE showed a genetic diversity among the 25 XDRAB isolates. Univariate analysis showed that long-term bed rest, hemodialysis, tracheostomy, use of glycopeptide, use of imipenem or meropenem, use of anti-pseudomonal penicillins, and use of the fourth generation cephalosporins, are statistically significant risk factors. Multiple conditional logistic regression analysis showed that, after adjusting for the effect of other variables, long-term bed rest (adjusted odds ratio 5.2, 95%CI: 1.1–24.4) and use of imipenem, meropenem, anti-pseudomonal penicillins, or the fourth-generation cephalosporins (adjusted odds ratio 4.3, 95%CI: 1.4–12.7) remain independent risk factors. We concluded that, for XDRAB HAIs control, it is essential to emphasize the prudent use of board-spectrum antibiotics active against gram-negative bacteria.

並列關鍵字

extensively drug-resisitant A. baumannii ； Pulsed-Field Gel Electrophoresis Analysis ； case-control study

參考文獻

1. Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest 1997;112:1050-4.

2. Scerpella EG, Wanger AR, Armitige L, Anderlini P, Ericsson CD. Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigations. Infect Control Hosp Epidemiol 1995;16:92-7.

3. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995;74:340-9.

4. Sunenshine RH, Wright MO, Maragakis LL, Harris AD,Song X,Hebden J,et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97-103.

5. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005;11:868-73.